AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02653911 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-acupuncture group
Description: Hwato Brand, Suzhou Medical Appliance Factory, China
Study NCT05204147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A
Description: Given IV
Study NCT05204147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04878315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capoten
Description: Capoten will be administered per the treatment sequence
Study NCT04878315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Captopril will be administered per the treatment sequence
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobile Dental Photography
Description: Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobile Dental Photography with cross-polarization filter
Description: Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobile Dental Photography with gray reference card
Description: Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a gray reference card
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobile Dental Photography with cross-polarization filter and gray reference card
Description: Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter and gray reference card
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital Camera
Description: Tooth color changes of 30 patients will be evaluated using a Digital Camera
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital Camera with cross-polarization filter
Description: Tooth color changes of 30 patients will be evaluated using a Digital Camera with cross-polarization filter
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital Camera with cross-polarization filter and gray reference card
Description: Tooth color changes of 30 patients will be evaluated using a Digital Camera with a cross-polarization filter and gray reference card
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital Camera with gray reference card
Description: Tooth color changes of 30 patients will be evaluated using a Digital Camera with a gray reference card
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rayplicker
Description: Tooth color changes of 30 patients will be evaluated using Rayplicker
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rayplicker with gray reference card
Description: Tooth color changes of 30 patients will be evaluated using Rayplicker with gray reference card
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vita Easyshade
Description: Tooth color changes of 30 patients will be evaluated using Vita Easyshade
Study NCT05620277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vita Easyshade with gray reference card
Description: Tooth color changes of 30 patients will be evaluated using Vita Easyshade with a gray reference card
Study NCT04792177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation skills training
Description: The intervention will involve an online emotion-regulation skills training for individuals with sexual problems. It will last for 8 weeks, encompassing psycho-educational and emotion-regulation skills components. Every week participants will gain access to a different intervention module of the training, containing videos, presentation slides, written support material and a recommendation of activities to be completed until the following week of training. Participants are expected to dedicate 30 minutes to one hour per week to complete each module.
Study NCT05554211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, TxA irrigation will be administered following gentamicin irrigation. TxA irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
Study NCT05554211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control normal saline (NS) irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
Study NCT05431764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, gemcitabin, cisplatin
Description: Patients receive gemcitabine (1000 mg/m² d1,8), cisplatin (80mg/m² d1), and camrelizumab (200mg, iv drip for over 60min) every 3 weeks for 6 cycles before locoregional radiotherapy.
Study NCT05431764 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
Description: IMRT: 5 fractions per week for 6 weeks to a total dose of 70 Gy and 33 fractions to the primary tumor.~SBRT: 3 months after locoregional IMRT, patients receive SBRT for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.~Camrelizumab (200mg, iv drip for over 60min) every 2 weeks began on the first day of IMRT until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years.
Study NCT04623749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US
Description: Percutaneous Ultrasound guided FNAC
Study NCT04623749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: Endoscopic Ultrasound guided FNAC
Study NCT04865029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo injection and placebo pill
Description: Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines
Study NCT04865029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Cypionate 5 mg/ml
Description: Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
Study NCT04865029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg Oral Capsule
Description: Standard of Care along with Progesterone 200mg by mouth daily for 5 days starting at admission.
Study NCT04749095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine
Study NCT04749095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sham subcutaneous infiltration
Description: bilateral ESP block will be injected with 20 ml of normal saline
Study NCT05259163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LFR-260 portable phoropter
Description: Portable unit to evaluate visual refractive state of the patient
Study NCT05259163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LFR-260 portable phoropter
Description: Portable unit to evaluate visual refractive state of the patient
Study NCT05259163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional phoropter (SOC)
Description: Standard unit for evaluating visual refractive state of the patient
Study NCT05259163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional phoropter (SOC)
Description: Standard unit for evaluating visual refractive state of the patient
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-115
Description: TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
Study NCT05045274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: 1. Dapagliflozin: It will be given in a dose of 10 mg once daily within 24 hours after PPCI.~2. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~3. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~4. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.
Study NCT05045274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.
Study NCT00691795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine or fentanyl
Description: After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
Study NCT05765643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse parental support in symptom management using a mobile health App
Description: Parents in this group will receive a mobile App that includes health assessment, monitoring, health education and nurse support using phone calls over a 3-month period
Study NCT05844059 — intervention group
Intervention type: OTHER
Intervention: Validated questionnaires
Description: BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.
Study NCT05741138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core strengthening
Description: Plank 1-3 sets of 10-15 reps per side at a slow tempo Side plank Draw in and lift, holding for 5 seconds with purposeful engagement of the core and leg musculature. Keep the head, shoulders, hips, knees and feet in a straight line.~Bridges - Lie supine with your knees bent and the feet flat on the floor. Lift your pelvis off the ground while supporting on your feet and shoulders. The bridge can be progressed by lifting one foot off the ground end extending the knee Leg rises - Lie on your back with your legs straight and your arms by your sides. Then lift one leg 4 inches of the ground. Your back has to stay flat on the floor. Don't allow it to arch. Alternate. The exercise can be progressed by lifting both legs at the same time.
Study NCT05741138 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Hot pack and TENS for 10 minutes (lumbar region and calf muscles) Ultrasound for 10 mins (lumbar region and calf muscles) Gentle passive stretching (calf muscles) Isometric exercises (lumbar region)
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB154
Description: AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
Study NCT04999761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
Study NCT04664101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)
Description: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
Study NCT04664101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparator
Description: Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
Study NCT06553690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Gym Therapy
Description: Brain Gym Therapy is a structured program of physical movements designed to enhance cognitive function, reduce stress, and promote relaxation. The therapy is based on the principle that specific physical activities can stimulate brain function and improve overall mental and physical well-being.
Study NCT05167422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trusted Messenger
Description: A nested waitlist design in which patients and staff are nested within two inpatient psychiatric units. New Hampshire Hospital staff will be trained to deliver the trusted messenger intervention up to 24 patients on the first unit while the second unit receives care as usual, during which time in-house vaccinations among patients on both units will be tracked in a registry. After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
Study NCT05953168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab Deruxtecan for TNBC-LAR patients with HER2 low expression
Study NCT05099432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CARMA technique
Description: Once standard polyp resection and assessment of the polypectomy site without magnification is completed, the CARMA technique will be applied. This will involve an assessment of the entire polypectomy margin using cap assisted magnification endoscopy with the ability to also use NBI (at the endoscopist's discretion) and documentation of any residual polyp noted.
Study NCT04950595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based mince
Description: Spaghetti bolognaise meal made with plant-based mince
Study NCT04950595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef mince
Description: Spaghetti bolognaise meal made with beef mince
Study NCT05630729 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: My Kidney Guru
Description: My Kidney Guru is a program that will offer pediatric patients with CKD developmentally appropriate, interactive, and engaging instruction and practice opportunities to build knowledge and skills to manage CKD.
Study NCT05714696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight discrimination experience
Description: In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion.
Study NCT05714696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control experience
Description: In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion.